

Vaxart to Present at Phacilitate's VAX 1-2-1 in Amsterdam on May 20, 2015

SOUTH SAN FRANCISCO, Calif., May 19, 2015 — Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, today announced that Vaxart CEO Wouter Latour, MD, will present a corporate overview at Phacilitate's VAX 1-2-1 in Amsterdam on Wednesday, May 20, 2015 at 3:30pm Central European Time. Dr. Latour will also take part in a panel discussion on vaccines on the same day, and he will be available to participate in one-on-one meetings during the meeting.

About Vaxart

Vaxart is a privately held, clinical-stage company developing tablet vaccines. The company's proprietary delivery platform is suitable to deliver any recombinant vaccine in oral form and allows rapid development to address emerging threats. Vaxart vaccines can be conveniently self-administered, with no cold chain distribution requirements and no medical waste. For more information, please visit www.vaxart.com.

###

CONTACT:

Katie Hogan

WCG

415.658.9745

khogan@wcgworld.com